Health Maintenance and Olmesartan

with additional studies

Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering. 1)

Although uncontrolled confounding might still exist, (this was a short term study) olmesartan does not seem to increase cardiovascular risk compared with losartan. 2)

The ROADMAP study will answer the question whether an ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor. can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. 3)

Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. 4)

Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaBA protein that stimulates the release of inflammatory cytokines in response to infection pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. (in breast cancer)5)

Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. 6)

Administration of olmesartan suppressed the accumulation of macrophages in brachiocephalic atherosclerotic plaque. (in mice) 7)

Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) 8)

Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system. IL-6 in the renovascular hypertensive rats. 9)

Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. 10)

Inhibition of renin-angiotensin system attenuates periadventitial inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. and reduces atherosclerotic lesion formation. 11)

Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. 12)

In conclusion, there is no robust signal for harm with olmesartan use. 13)

General research on aging

Holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin D, daily or as a bolus, does not reduce the risk of cardiovascular events. 14)

When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. 15)

Some of the documented protective effects of ARBs

include the ability to:

  • decrease the incidence and progression of Alzheimer's disease and dementia16)
  • prevent migraines17)
  • inhibit liver fibrosis and aid liver healing18)
  • reduce insulin resistance in rats19)
  • 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats20)
  • protect mitochondria from age-associated damage from oxidation21)
  • play a protective role against proliferative diabetic retinopathy 22)
  • reduce liver fibrosis23)
  • treatment of anxiety and stress-related disorders24)
  • reduce oxidative damage25) and limit aging 26) 27)

Olmesartan and other ARBs have been used

to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:

  • protect the heart from damage from inflammation in myocarditis28)
  • prevent acute left ventricular dysfunction30)
  • lower C-reactive protein, one of the acute phase proteins that increase during systemic inflammation31)
  • act as an antiarrhythmic32)
  • block the production of Angiotensin II, thus improving mortality rates in heart failure patients33)
  • This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy. 34)
  • Conclusion: In the present study, left ventricular hypertrophy and on arterial compliance were inhibited by a decrease in angiotensin II and aldosterone due to the change-over to olmesartan. In the future, protective effects on organs will be clarified by long-term observations. 35) 36)


80mg single dose vs 6hrlydosing
4 hourly compared to 6 hourly dosing

In August 2002, Trevor Marshall and Frances Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARB caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.

In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss37). That would be 9-10 tablets of Olmetec daily for a 64 Kg human !

For those with gastric issues, it is recommended that the pill be crushed and mixed with applesauce or similar to reduce impact on gastric lining.

Olmesartan has also been shown to

  • prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes 38)
  • reduce the volume of atherosclerotic plaques39) 40)
  • mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).41)
  • significantly remodel and destiffen the arterial wall material during long-term treatment 42)

A number of studies have found

that olmesartan possesses various ways of protecting the kidneys from the effects of inflammation and cytokine damage:

  • in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization 43)
  • in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition 44)
  • results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis 45)
  • renal protective effects of olmesartan may be better than those of other ARBs 46)
  • olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects 47)

Studies also showed

  • treatment with olmesartan inhibited bone loss 48)
  • olmesartan protects endothelial cells against oxidative stress-mediated cellular injury 49)
  • decreases viability of malignant cell lines50)
  • carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques 51)
  • improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan 52)
  • improvement of glycemic control & insulin resistance was only observed in olmesartan group 53)
  • OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes 54)
  • prevention of microalbuminuria in patients with type 2 diabetes and hypertension 55)

Long term treatment

Patients receiving the highest dose of olmesartan (40 and 80 mg) had an inward carotid remodeling and were shifted toward a lower elastic modulus at a given circumferential wall stress, indicating an improvement in the intrinsic elastic properties of the carotid artery wall material. These data suggest that 40 and 80 mg olmesartan were able to significantly remodel and destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg.

hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint 56)

Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005 Dec;16(12):3631-41. doi: 10.1681/ASN.2005050522. Epub 2005 Oct 19.
[PMID: 16236804] [DOI: 10.1681/ASN.2005050522]
Lin J, Chang C, Caffrey JL, Wu L, Lai M. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality. Hypertension. 2014 May;63(5):968-76. doi: 10.1161/HYPERTENSIONAHA.113.02550. Epub 2014 Feb 10.
[PMID: 24516110] [DOI: 10.1161/HYPERTENSIONAHA.113.02550]
Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JLJ, Januszewicz A. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6.
[PMID: 16508590] [DOI: 10.1097/01.hjh.0000202820.56201.e6]
Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. 2014;3(2):e000810. doi: 10.1161/jaha.114.000810.
[PMID: 24772521] [PMCID: 4187490] [DOI: 10.1161/jaha.114.000810]
5) , 7) , 8) , 10)
Syntax error [pubmed plugin]
Schmieder RE, Bramlage P, Haller H, Ruilope LM, Böhm M, ROADMAP Investigators. The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. Medicine (Baltimore). 2016 Apr;95(15):e3122. doi: 10.1097/MD.0000000000003122.
[PMID: 27082551] [PMCID: 4839795] [DOI: 10.1097/MD.0000000000003122]
Li Z, Yu H, Wang X, Zhang M, Wang J. Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats. Eur Rev Med Pharmacol Sci. 2013 Dec;17(24):3318-22.
[PMID: 24379062]
Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother. 2009 Dec;63(10):754-61. doi: 10.1016/j.biopha.2009.02.006. Epub 2009 Mar 10.
[PMID: 19304450] [DOI: 10.1016/j.biopha.2009.02.006]
Mendell J, Matsushima N, O'Reilly TE, Lee J. A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval. J Clin Pharmacol. 2016 Apr;56(4):484-91. doi: 10.1002/jcph.610. Epub 2015 Nov 9.
[PMID: 26239632] [PMCID: 5063153] [DOI: 10.1002/jcph.610]
Padwal R, Lin M, Etminan M, Eurich DT. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension. 2014 May;63(5):977-83. doi: 10.1161/HYPERTENSIONAHA.113.02855. Epub 2014 Feb 17.
[PMID: 24535009] [DOI: 10.1161/HYPERTENSIONAHA.113.02855]
Lewis JR, Sim M, Daly RM. The vitamin D and calcium controversy: an update. Curr Opin Rheumatol. 2019 Mar;31(2):91-97. doi: 10.1097/BOR.0000000000000584.
[PMID: 30601231] [DOI: 10.1097/BOR.0000000000000584]
Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence-based medicine against falls risk. Postgrad Med. 2015 Apr;127(3):330-7. doi: 10.1080/00325481.2014.996112. Epub 2014 Dec 24.
[PMID: 25539567] [DOI: 10.1080/00325481.2014.996112]
Li N, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010 Jan 12;340:b5465. doi: 10.1136/bmj.b5465.
[PMID: 20068258] [PMCID: 2806632] [DOI: 10.1136/bmj.b5465]
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1;289(1):65-9. doi: 10.1001/jama.289.1.65.
[PMID: 12503978] [DOI: 10.1001/jama.289.1.65]
Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol. 2003 Jul;139(6):1085-94. doi: 10.1038/sj.bjp.0705339.
[PMID: 12871826] [PMCID: 1573934] [DOI: 10.1038/sj.bjp.0705339]
Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res. 2004 Apr;27(4):293-9. doi: 10.1291/hypres.27.293.
[PMID: 15127887] [DOI: 10.1291/hypres.27.293]
20) , 37)
Araújo AA, Lopes de Souza G, Souza TO, de Castro Brito GA, Sabóia Aragão K, Xavier de Medeiros CA, Lourenço Y, do Socorro Costa Feitosa Alves M, Fernandes de Araújo RJ. Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386(10):875-84. doi: 10.1007/s00210-013-0886-8. Epub 2013 Jun 19.
[PMID: 23775504] [DOI: 10.1007/s00210-013-0886-8]
de Cavanagh EMV, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 2003 Jun;17(9):1096-8. doi: 10.1096/fj.02-0063fje. Epub 2003 Apr 22.
[PMID: 12709417] [DOI: 10.1096/fj.02-0063fje]
Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res. 2008 Jan;75(1):130-4. doi: 10.1016/j.mvr.2007.05.001. Epub 2007 May 18.
[PMID: 17560613] [DOI: 10.1016/j.mvr.2007.05.001]
Oakley F, Teoh V, Ching-A-Sue G, Bataller R, Colmenero J, Jonsson JR, Eliopoulos AG, Watson MR, Manas D, Mann DA. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology. 2009 Jun;136(7):2334-2344.e1. doi: 10.1053/j.gastro.2009.02.081. Epub 2009 Mar 18.
[PMID: 19303015] [DOI: 10.1053/j.gastro.2009.02.081]
Saavedra JM, Ando H, Armando I, Baiardi G, Bregonzio C, Juorio A, Macova M. Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept. 2005 Jun 30;128(3):227-38. doi: 10.1016/j.regpep.2004.12.015.
[PMID: 15837532] [DOI: 10.1016/j.regpep.2004.12.015]
Cal LA, Maso LD, Caielli P, Pagnin E, Fusaro M, Davis PA, Pessina AC. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence. Blood Press. 2011 Dec;20(6):376-82. doi: 10.3109/08037051.2011.575570. Epub 2011 Apr 20.
[PMID: 21504378] [DOI: 10.3109/08037051.2011.575570]
Cassis P, Conti S, Remuzzi G, Benigni A. Angiotensin receptors as determinants of life span. Pflugers Arch. 2010 Jan;459(2):325-32. doi: 10.1007/s00424-009-0725-4. Epub 2009 Sep 11.
[PMID: 19763608] [DOI: 10.1007/s00424-009-0725-4]
Capettini LSA, Montecucco F, Mach F, Stergiopulos N, Santos RAS, da Silva RF. Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des. 2012;18(7):963-70. doi: 10.2174/138161212799436593.
[PMID: 22283774] [DOI: 10.2174/138161212799436593]
Seko Y. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. Clin Sci (Lond). 2006 Mar;110(3):379-86. doi: 10.1042/CS20050299.
[PMID: 16336207] [DOI: 10.1042/CS20050299]
Yuan Z, Nimata M, Okabe T, Shioji K, Hasegawa K, Kita T, Kishimoto C. Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1147-52. doi: 10.1152/ajpheart.00078.2005. Epub 2005 May 6.
[PMID: 15879491] [DOI: 10.1152/ajpheart.00078.2005]
Ohta T, Hasebe N, Tsuji S, Izawa K, Jin Y, Kido S, Natori S, Sato M, Kikuchi K. Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2914-21. doi: 10.1152/ajpheart.00221.2004. Epub 2004 Aug 5.
[PMID: 15297251] [DOI: 10.1152/ajpheart.00221.2004]
Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006 Spring;24(1):33-50. doi: 10.1111/j.1527-3466.2006.00033.x.
[PMID: 16939632] [DOI: 10.1111/j.1527-3466.2006.00033.x]
Boos CJ, Lip GYH. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens. 2005 Nov;19(11):855-9. doi: 10.1038/sj.jhh.1001933.
[PMID: 16094406] [DOI: 10.1038/sj.jhh.1001933]
Schulz R, Heusch G. Angiotensin II in the failing heart. Short communication. Kidney Blood Press Res. 2005;28(5-6):349-52. doi: 10.1159/000090189. Epub 2006 Mar 7.
[PMID: 16534230] [DOI: 10.1159/000090189]
Sezai A, Osaka S, Yaoita H, Arimoto M, Hata H, Shiono M, Sakino H. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). Ann Thorac Cardiovasc Surg. 2016 Jun 20;22(3):161-7. doi: 10.5761/atcs.oa.16-00054. Epub 2016 Apr 18.
[PMID: 27086671] [PMCID: 4909997] [DOI: 10.5761/atcs.oa.16-00054]
Sezai A, Soma M, Hata M, Yoshitake I, Unosawa S, Wakui S, Shiono M. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. Ann Thorac Cardiovasc Surg. 2011;17(5):487-93. doi: 10.5761/atcs.oa.11.01691. Epub 2011 Jul 27.
[PMID: 21881353] [DOI: 10.5761/atcs.oa.11.01691]
Daikuhara H, Fukunaga K, Ohshima T. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. Drug Des Devel Ther. 2014 Feb 17;8:219-26. doi: 10.2147/DDDT.S53253. eCollection 2014.
[PMID: 24600204] [PMCID: 3933665] [DOI: 10.2147/DDDT.S53253]
38) , 54)
Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE. Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. J Hypertens. 2014 Nov;32(11):2267-76; discussion 2276. doi: 10.1097/HJH.0000000000000313.
[PMID: 25275251] [DOI: 10.1097/HJH.0000000000000313]
39) , 51)
Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M, MORE study investigators. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007 Dec;1(2):97-106. doi: 10.1177/1753944707085982.
[PMID: 19124398] [DOI: 10.1177/1753944707085982]
Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010 Mar 9;55(10):976-82. doi: 10.1016/j.jacc.2009.09.062.
[PMID: 20202514] [DOI: 10.1016/j.jacc.2009.09.062]
Lu G, Cheng J, Zhu K, Ma X, Shen F, Su D. A systematic review of angiotensin receptor blockers in preventing stroke. Stroke. 2009 Dec;40(12):3876-8. doi: 10.1161/STROKEAHA.109.559989. Epub 2009 Nov 5.
[PMID: 19892999] [DOI: 10.1161/STROKEAHA.109.559989]
42) , 56)
Laurent S, Boutouyrie P, Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014 Oct;64(4):709-16. doi: 10.1161/HYPERTENSIONAHA.114.03282. Epub 2014 Jul 7.
[PMID: 25001274] [DOI: 10.1161/HYPERTENSIONAHA.114.03282]
Sato R, Mizuno M, Miura T, Kato Y, Watanabe S, Fuwa D, Ogiyama Y, Tomonari T, Ota K, Ichikawa T, Shirasawa Y, Ito A, Yoshida A, Fukuda M, Kimura G. Angiotensin receptor blockers regulate the synchronization of circadian rhythms in heart rate and blood pressure. J Hypertens. 2013 Jun;31(6):1233-8. doi: 10.1097/HJH.0b013e32836043c9.
[PMID: 23511341] [DOI: 10.1097/HJH.0b013e32836043c9]
Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res. 2013 Mar;36(3):262-9. doi: 10.1038/hr.2012.184. Epub 2012 Nov 15.
[PMID: 23154587] [PMCID: 3594468] [DOI: 10.1038/hr.2012.184]
Honda H, Hosaka N, Aoshima Y, Hirai Y, Michihata T, Akizawa T. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients. Clin Exp Hypertens. 2012;34(1):17-23. doi: 10.3109/10641963.2011.628726. Epub 2011 Dec 9.
[PMID: 22149003] [DOI: 10.3109/10641963.2011.628726]
Ono T, Sanai T, Miyahara Y, Noda R. Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy. Curr Ther Res Clin Exp. 2013 Jun;74:62-7. doi: 10.1016/j.curtheres.2013.02.002.
[PMID: 24384547] [PMCID: 3862195] [DOI: 10.1016/j.curtheres.2013.02.002]
Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, Shibata S, Tanaka M, Watanabe Y, Akasaka H, Ohnishi H, Yoshida H, Takizawa H, Saitoh S, Ura N, Shimamoto K, Miura T. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015 Jan;28(1):15-21. doi: 10.1093/ajh/hpu086. Epub 2014 May 18.
[PMID: 24842388] [DOI: 10.1093/ajh/hpu086]
Aoki M, Kawahata H, Sotobayashi D, Yu H, Moriguchi A, Nakagami H, Ogihara T, Morishita R. Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. Geriatr Gerontol Int. 2015 Aug;15(8):1064-72. doi: 10.1111/ggi.12406. Epub 2014 Nov 3.
[PMID: 25363367] [DOI: 10.1111/ggi.12406]
Kadowaki D, Anraku M, Sakaya M, Hirata S, Maruyama T, Otagiri M. Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury. Clin Exp Nephrol. 2015 Dec;19(6):1007-14. doi: 10.1007/s10157-015-1111-5. Epub 2015 Apr 23.
[PMID: 25904217] [DOI: 10.1007/s10157-015-1111-5]
Bakhtiari E, Hosseini A, Mousavi SH. The role of ROS and NF-κB pathway in olmesartan induced-toxicity in HeLa and mcf-7 cell lines. Biomed Pharmacother. 2017 Sep;93:429-434. doi: 10.1016/j.biopha.2017.06.074. Epub 2017 Jun 27.
[PMID: 28666209] [DOI: 10.1016/j.biopha.2017.06.074]
Tada Y, Yagi K, Uno M, Matsushita N, Kanematsu Y, Kuwayama K, Shimada K, Nishi K, Hirasawa M, Satomi J, Kitazato KT, Kageji T, Matsuura E, Nagahiro S. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan. J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1487-92. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.015. Epub 2015 Apr 16.
[PMID: 25891757] [DOI: 10.1016/j.jstrokecerebrovasdis.2015.03.015]
Arao T, Okada Y, Mori H, Nishida K, Tanaka Y. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J. 2013;60(5):563-70. doi: 10.1507/endocrj.ej12-0326. Epub 2013 Jan 10.
[PMID: 23303198] [DOI: 10.1507/endocrj.ej12-0326]
Menne J, Izzo JLJ, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H, ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d.
[PMID: 22418908] [DOI: 10.1097/HJH.0b013e328351856d]
home/food/aim_health/aging.txt · Last modified: 09.14.2022 by
© 2015, Autoimmunity Research Foundation. All Rights Reserved.